The current market price of Nippon India NIFTY Pharma ETF Growth Plan is ₹27.20. ETF prices fluctuate during market hours based on demand, supply, and movements in the underlying index or assets.

Nippon India NIFTY Pharma ETF Growth Plan by Nippon Life India Asset Management Limited aims to replicate NIFTY Pharma Index as an open-ended Equity - ETF with Passive investment style. Replicating the Nifty Pharma TRI through passive replication, the ETF emphasises close benchmark adherence and delivers tracking efficiency, evidenced by a tracking error of 0.0% which indicates tight tracking. Portfolio concentrated in Pharmaceuticals & Biotechnology with top-ten positions comprising 78.0% of assets; largest allocations include Sun Pharmaceutical 21.4%, Divi's Laboratories 9.5% and Dr. Reddy's 8.9% indicating concentration risk. Performance has been strong over the available one-year window, returning +24.2% (1Y), with no multi-year CAGR data provided; low tracking error complements benchmark alignment though volatility metrics are not available. Operationally the ETF manages ₹1570.2 Cr (AUM as on May 2026) with monthly average ₹1520.4 Cr, expense ratio 0.2% and manager Jitendra Tolani managing since Feb 2025, 19 years' experience.

Nippon India NIFTY Pharma ETF Growth Plan is designed to track Nifty Pharma TRI, allowing investors to gain exposure to its underlying securities through a single investment.

The expense ratio of Nippon India NIFTY Pharma ETF Growth Plan is 0.18%. This represents the annual fee charged by the fund house for managing the ETF and is deducted from the fund’s assets.

The Assets Under Management (AUM) of Nippon India NIFTY Pharma ETF Growth Plan is approximately ₹1,570.17. AUM reflects the total market value of assets managed by the ETF and is often used as an indicator of fund size and liquidity.

Nippon India NIFTY Pharma ETF Growth Plan is classified under the as per the risk-o-meter defined by the fund house risk category. The risk level depends on the volatility of the underlying index, market conditions, and asset composition of the ETF.

The tracking error of Nippon India NIFTY Pharma ETF Growth Plan is 0.02%. Tracking error measures how closely the ETF’s performance matches its benchmark index over time.

Nippon India NIFTY Pharma ETF Growth Plan has a dividend yield of 0.67%. Dividend treatment depends on the ETF structure and fund house policy.

Based on available data, Nippon India NIFTY Pharma ETF Growth Plan has delivered the following returns: 1-year return: 21.92%. 3-year return: 73.69%. 5-year return: 86.56%. Past performance does not guarantee future results.

Before investing in Nippon India NIFTY Pharma ETF Growth Plan, investors generally consider the underlying index, expense ratio, tracking error, risk profile, liquidity, and how the ETF fits within their overall portfolio strategy.